This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Japanese Foundation for Cancer Research. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Takaya Sekiguchi: Innovator in Cancer Research
Introduction
Takaya Sekiguchi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research, particularly through his innovative work on monoclonal antibodies. His research focuses on the Aggrus-CLEC-2 binding mechanism, which plays a crucial role in cancer metastasis.
Latest Patents
Takaya Sekiguchi holds a patent for an "Anti-Aggrus monoclonal antibody, domain in Aggrus which is required for binding to CLEC-2, and method for screening for Aggrus-CLEC-2 binding inhibitor." This patent describes a novel domain of Aggrus that is essential for its binding to CLEC-2. The research led to the development of monoclonal antibodies that recognize this domain, known as the PLAG4 domain. These antibodies have the potential to serve as Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, cancer metastasis inhibitors, and tumor growth inhibitors.
Career Highlights
Takaya Sekiguchi is affiliated with the Japanese Foundation for Cancer Research, where he continues to advance his research. His work has garnered attention for its potential applications in cancer treatment and prevention. With a focus on innovative solutions, Sekiguchi aims to contribute to the development of effective therapies for cancer patients.
Collaborations
He collaborates with notable colleagues, including Naoya Fujita and Satoshi Takagi. Their combined expertise enhances the research efforts at the Japanese Foundation for Cancer Research.
Conclusion
Takaya Sekiguchi's innovative work in cancer research, particularly through his patent on monoclonal antibodies, showcases his commitment to advancing medical science. His contributions have the potential to significantly impact cancer treatment and improve patient outcomes.